BioSpace News Archive

- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis - Company Reaffirms it is on Schedule to Complete PRV-031 (teplizumab) Rolling BLA Submission for Prevention or Delay of T1D in At-risk Individuals

INVO’s novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility market

Digital health and supply chain entrepreneurs Randy Parker and Glenn Nussdorf today announced the launch of Genius Rx, a full-service, fully automated digital pharmacy that will use proprietary technology to make pharmacy services simple, intuitive and personal for consumers.

Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved reversal agent for the Facto

March 16, 2020 12:00 UTC SAN DIEGO--( BUSINESS WIRE )-- Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of genome structure information toward medical research, diagnosis and therapy, announced today the full commercial launch of the HiChIP application built on its existing Arima-HiC platform. With this launch, researchers can now obtain long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest

Enhanced digital strategy increases lab efficiencies and productivity

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. financial markets.

PreCheck Health Services, Inc. (OTC PINK: HLTY), a distributor of medical screening devices for use by physicians in managing a patient’s health, announces its third distribution agreement for Co-Diagnostics’ Coronavirus COVID-19 PCR test.

Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of Research-Use Only (RUO) target enrichment next-generation sequencing (NGS) panels for viral detection and characterization of samples from patients testing positive for SARS-CoV-2, the virus which causes COVID-19. These panels can be used for environmental monitoring and surveillance testing, while also providing insight into ful

TRACON Pharmaceuticals announced today that it has submitted a request for a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the trial